Luznik, L, O’Donnell, PV, Fuchs, EJ. Post-transplantation cyclophosphamide for tolerance induction in HLA-haploidentical bone marrow transplantation. Semin Oncol. 2012;39(6):683–93.CrossRefGoogle ScholarPubMed

Martin, PJ, Rizzo, JD, Wingard, JR, Ballen, K, Curtin, PT, Cutler, C, et al. First-and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2012;18(8):1150–63.Google ScholarPubMed

Ruutu, T, Gratwohl, A, de Witte, T, Afanasyev, B, Apperley, J, Bacigalupo, A, et al. Prophylaxis and treatment of GVHD: EBMT-ELN working group recommendations for a standardized practice. Bone Marrow Transplant. 2014;49(2):168–73Google Scholar

Wolff, D, Ayuk, F, Elmaagacli, A, Bertz, H, Lawitschka, A, Schleuning, M, et al. Current practice in diagnosis and treatment of acute graft-versus-host disease: results from a survey among German-Austrian-Swiss hematopoietic stem cell transplant centers. Biol Blood Marrow Transplant. 2013;19(5):767–76.CrossRefGoogle ScholarPubMed

Salmasian, H, Rohanizadegan, M, Banihosseini, S, Rahimi Darabad, R, Rabbani-Anari, M, Shakiba, A, Ferrara, JL. Corticosteroid regimens for treatment of acute and chronic graft versus host disease (GvHD) after allogenic stem cell transplantation. Cochrane Database Syst Rev. 2010;(1):CD005565.Google Scholar

Alousi, AM, Weisdorf, DJ, Logan, BR, Bolaños-Meade, J, Carter, S, Difronzo, N, et al. Blood and Marrow Transplant Clinical Trials Network. Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network. Blood. 2009;114(3):511–7.CrossRefGoogle ScholarPubMed

Bolaños-Meade, J, Logan, BR, Alousi, AM, Antin, JH, Barowski, K, Carter, SL, et al. Phase 3 clinical trial of steroids/mycophenolate mofetil vs steroids/placebo as therapy for acute GVHD: BMT CTN 0802. Blood. 2014;124(22):3221–7.CrossRefGoogle ScholarPubMed

Couriel, DR, Saliba, R, de Lima, M, Giralt, S, Andersson, B, Khouri, I, et al. A phase III study of infliximab and corticosteroids for the initial treatment of acute graft-versus-host disease. Biol Blood Marrow Transplant. 2009;15(12):1555–62.CrossRefGoogle ScholarPubMed

Gatza, E, Braun, T, Levine, JE, Ferrara, JL, Zhao, S, Wang, T, et al. Etanercept plus topical corticosteroids as initial therapy for grade one acute graft-versus-host disease after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2014;20(9):1426–34.CrossRefGoogle ScholarPubMed

Takashima, S, Eto, T, Shiratsuchi, M, Hidaka, M, Mori, Y, Kato, K, et al. The use of oral beclomethasone dipropionate in the treatment of gastrointestinal graft-versus-host disease: the experience of the Fukuoka blood and marrow transplantation (BMT) group. Intern Med. 2014;53(12):1315–20.CrossRefGoogle ScholarPubMed

Bürgler, D, Medinger, M, Passweg, J, Fischmann, A, Bucher, C. Intra-arterial catheter guided steroid administration for the treatment of steroid-refractory intestinal GvHD. Leuk Res. 2014;38(2):184–7.CrossRefGoogle ScholarPubMed

Milner, LA, Becker, MW, Bernstein, SH, Bruckner, L, Friedberg, JW, Holland, GA, et al. Intra-arterial methylprednisolone for the management of steroid-refractory acute gastrointestinal and hepatic graft versus host disease. Am J Hematol. 2011;86(8):712–4.CrossRefGoogle ScholarPubMed

Feldstein, JV, Bolaños-Meade, J, Anders, VL, Abuav, R. Narrowband ultraviolet B phototherapy for the treatment of steroid-refractory and steroid-dependent acute graft-versus-host disease of the skin. J Am Acad Dermatol. 2011;65(4):733–8.CrossRefGoogle ScholarPubMed

Hoda, D, Pidala, J, Salgado-Vila, N, Kim, J, Perkins, J, Bookout, R, et al. Sirolimus for treatment of steroid-refractory acute graft-versus-host disease. Bone Marrow Transplant. 2010;45(8):1347–51.CrossRefGoogle ScholarPubMed

Mielke, S, Lutz, M, Schmidhuber, J, Kapp, M, Ditz, D, Ammer, J, et al. Salvage therapy with everolimus reduces the severity of treatment-refractory chronic GVHD without impairing disease control: A dual center retrospective analysis. Bone Marrow Transplant. 2014;49(11):1412–8.CrossRefGoogle ScholarPubMed

García-Cadenas, I, Valcárcel, D, Martino, R, Piñana, JL, Novelli, S, Esquirol, A, et al. Updated experience with inolimomab as treatment for corticosteroid-refractory acute graft-versus-host disease. Biol Blood Marrow Transplant. 2013;19(3):435–9.CrossRefGoogle ScholarPubMed

Wang, JZ, Liu, KY, Xu, LP, Liu, DH, Han, W, Chen, H, et al. Basiliximab for the treatment of steroid-refractory acute graft-versus-host disease after unmanipulated HLA-mismatched/haploidentical hematopoietic stem cell transplantation. Transplant Proc. 2011;43(5):1928–33.CrossRefGoogle ScholarPubMed

Xhaard, A, Rocha, V, Bueno, B, de Latour, RP, Lenglet, J, Petropoulou, A, et al. Steroid-refractory acute GvHD: lack of long-term improved survival using new generation anticytokine treatment. Biol Blood Marrow Transplant. 2012;18(3):406–13.CrossRefGoogle ScholarPubMed

Drobyski, WR, Pasquini, M, Kovatovic, K, Palmer, J, Douglas Rizzo, J, Saad, A, et al. Tocilizumab for the treatment of steroid refractory graft-versus-host disease. Biol Blood Marrow Transplant. 2011;17(12):1862–8.CrossRefGoogle ScholarPubMed

Meunier, M, Bulabois, CE, Thiebaut-Bertrand, A, Itzykson, R, Carre, M, Carras, S, et al. Alemtuzumab for severe steroid-refractory gastrointestinal acute graft-versus-host disease. Biol Blood Marrow Transplant. 2014;20(9):1451–4.CrossRefGoogle ScholarPubMed

Khandelwal, P, Lawrence, J, Filipovich, AH, Davies, SM, Bleesing, JJ, Jordan, MB, et al. The successful use of alemtuzumab for treatment of steroid-refractory acute graft-versus-host disease in pediatric patients. Pediatr Transplant. 2014;18(1):94–102.CrossRefGoogle ScholarPubMed

Schub, N, Günther, A, Schrauder, A, Claviez, A, Ehlert, C, Gramatzki, M, Repp, R. Therapy of steroid-refractory acute GVHD with CD52 antibody alemtuzumab is effective. Bone Marrow Transplant. 2011;46(1):143–7.CrossRefGoogle ScholarPubMed

Abu-Dalle, I, Reljic, T, Nishihori, T, Antar, A, Bazarbachi, A, Djulbegovic, B,et al. Extracorporeal photopheresis in steroid-refractory acute or chronic graft-versus-host disease: results of a systematic review of prospective studies. Biol Blood Marrow Transplant. 2014;20(11):1677–86.CrossRefGoogle ScholarPubMed

Das-Gupta, E, Dignan, F, Shaw, B, Raj, K, Malladi, R, Gennery, A, et al. Extracorporeal photopheresis for treatment of adults and children with acute GvHD: UK consensus statement and review of published literature. Bone Marrow Transplant. 2014;49(10):1251–8.CrossRefGoogle ScholarPubMed

Pierelli, L, Perseghin, P, Marchetti, M, Messina, C, Perotti, C, Mazzoni, A, et al.; Società Italiana di Emaferesi and Manipolazione Cellulare (SIdEM); Gruppo Italiano Trapianto Midollo Osseo (GITMO). Extracorporeal photopheresis for the treatment of acute and chronic graft-versus-host disease in adults and children: best practice recommendations from an Italian Society of Hemapheresis and Cell Manipulation (SIdEM) and Italian Group for Bone Marrow Transplantation (GITMO) consensus process. Transfusion. 2013;53(10):2340–52.CrossRefGoogle Scholar

Jagasia, M, Greinix, H, Robin, M, Das-Gupta, E, Jacobs, R, Savani, BN, et al. Extracorporeal photopheresis versus anticytokine therapy as a second-line treatment for steroid-refractory acute GVHD: a multicenter comparative analysis. Biol Blood Marrow Transplant. 2013;19(7):1129–33.CrossRefGoogle ScholarPubMed

Rieber, N, Wecker, I, Neri, D, Fuchs, K, Schäfer, I, Brand, A, et al. Extracorporeal photopheresis increases neutrophilic myeloid-derived suppressor cells in patients with GvHD. Bone Marrow Transplant. 2014;49(4):545–52.CrossRefGoogle ScholarPubMed

Mevorach, D, Zuckerman, T, Reiner, I, Shimoni, A, Samuel, S, Nagler, A, et al. Single infusion of donor mononuclear early apoptotic cells as prophylaxis for graft-versus-host disease in myeloablative HLA-matched allogeneic bone marrow transplantation: a phase I/IIa clinical trial. Biol Blood Marrow Transplant. 2014;20(1):58–65.CrossRefGoogle Scholar

Sánchez-Guijo, F, Caballero-Velázquez, T, López-Villar, O, Redondo, A, Parody, R, Martínez, C, et al. Sequential third-party mesenchymal stromal cell therapy for refractory acute graft-versus-host disease. Biol Blood Marrow Transplant. 2014;20(10):1580–5.CrossRefGoogle ScholarPubMed

Introna, M, Lucchini, G, Dander, E, Galimberti, S, Rovelli, A, Balduzzi, A, et al. Treatment of graft versus host disease with mesenchymal stromal cells: a phase I study on 40 adult and pediatric patients. Biol Blood Marrow Transplant. 2014;20(3):375–81.CrossRefGoogle ScholarPubMed

Ball, LM, Bernardo, ME, Roelofs, H, van Tol, MJ, Contoli, B, Zwaginga, JJ, et al. Multiple infusions of mesenchymal stromal cells induce sustained remission in children with steroid-refractory, grade III–IV acute graft-versus-host disease. Br J Haematol 2013;163(4):501–9.CrossRefGoogle ScholarPubMed

Schneidawind, D, Pierini, A, Negrin, RS. Regulatory T cells and natural killer T cells for modulation of GvHD following allogeneic hematopoietic cell transplantation. Blood. 2013;122(18):3116–21.CrossRefGoogle ScholarPubMed

Reddy, P. Targeting deacetylases to improve outcomes after allogeneic bone marrow transplantation. Trans Am Clin Climatol Assoc. 2013;124:152–62.Google ScholarPubMed

Marcondes, AM, Li, X, Tabellini, L, Bartenstein, M, Kabacka, J, Sale, GE, et al. Inhibition of IL-32 activation by α-1 antitrypsin suppresses alloreactivity and increases survival in an allogeneic murine marrow transplantation model. Blood. 2011;118(18):5031–9.CrossRefGoogle Scholar

Tawara, I, Sun, Y, Lewis, EC, Toubai, T, Evers, R, Nieves, E, et al. Alpha-1-antitrypsin monotherapy reduces graft-versus-host disease after experimental allogeneic bone marrow transplantation. Proc Natl Acad Sci U S A. 2012;109(2):564–9.CrossRefGoogle ScholarPubMed

Landfried, K, Zhu, W, Waldhier, MC, Schulz, U, Ammer, J, Holler, B, et al. Tryptophan catabolism is associated with acute GvHD after human allogeneic stem cell transplantation and indicates activation of indoleamine 2,3-dioxygenase. Blood. 2011;118(26):6971–4.CrossRefGoogle ScholarPubMed

Elmaagacli, AH, Ditschkowski, M, Steckel, NK, Gromke, T, Ottinger, H, Hillen, U, et al. Human chorionic gonadotropin and indolamine 2,3-dioxygenase in patients with GvHD. Bone Marrow Transplant. 2014;49(6):800–5.CrossRefGoogle ScholarPubMed

Holler, E, Butzhammer, P, Schmid, K, Hundsrucker, C, Koestler, J, Peter, K, et al. Metagenomic analysis of the stool microbiome in patients receiving allogeneic stem cell transplantation: loss of diversity is associated with use of systemic antibiotics and more pronounced in gastrointestinal graft-versus-host disease. Biol Blood Marrow Transplant. 2014;20(5):640–5.CrossRefGoogle ScholarPubMed

Jenq, RR, Ubeda, C, Taur, Y, Menezes, CC, Khanin, R, Dudakov, JA, et al. Regulation of intestinal inflammation by microbiota following allogeneic bone marrow transplantation. J Exp Med. 2012;209(5):903–11.CrossRefGoogle ScholarPubMed

Eriguchi, Y, Takashima, S, Oka, H, Shimoji, S, Nakamura, K, Uryu, H, et al. Graft-versus-host disease disrupts intestinal microbial ecology by inhibiting Paneth cell production of α-defensins. Blood. 2012;120(1):223–31.CrossRefGoogle ScholarPubMed

Munneke, JM, Björklund, AT, Mjösberg, JM, Garming-Legert, K, Bernink, JH, Blom, B, et al. Activated innate lymphoid cells are associated with a reduced susceptibility to graft-versus-host disease. Blood. 2014;124(5):812–21.CrossRefGoogle ScholarPubMed

Hanash, AM, Dudakov, JA, Hua, G, O’Connor, MH, Young, LF, Singer, NV, et al. Interleukin-22 protects intestinal stem cells from immune-mediated tissue damage and regulates sensitivity to graft versus host disease. Immunity. 2012;37(2):339–50.CrossRefGoogle ScholarPubMed

Spoerl, S, Mathew, NR, Bscheider, M, Schmitt-Graeff, A, Chen, S, Mueller, T, et al. Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease. Blood. 2014;123(24):3832–42.CrossRefGoogle ScholarPubMed

Pai, CC, Hsiao, HH, Sun, K, Chen, M, Hagino, T, Tellez, J, et al. Therapeutic benefit of bortezomib on acute graft-versus-host disease is tissue specific and is associated with interleukin-6 levels. Biol Blood Marrow Transplant. 2014 Jul 23. pii: S1083-8791(14)00448-0. doi: 10.1016/j.bbmt.2014.07.022. [Epub ahead of print]CrossRefGoogle Scholar

Castilla-Llorente, C, Martin, PJ, McDonald, GB, Storer, BE, Appelbaum, FR, Deeg, HJ, et al. Prognostic factors and outcomes of severe gastrointestinal GVHD after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2014;49(7):966–71.CrossRefGoogle ScholarPubMed

Ayuk, F, Bussmann, L, Zabelina, T, Veit, R, Alchalby, H, Wolschke, C, et al. Serum albumin level predicts survival of patients with gastrointestinal acute graft-versus-host disease after allogeneic stem cell transplantation. Ann Hematol. 2014;93(5):855–61.CrossRefGoogle ScholarPubMed

MacMillan, ML, DeFor, TE, Weisdorf, DJ. What predicts high risk acute graft-versus-host disease (GvHD) at onset?: identification of those at highest risk by a novel acute GvHD risk score. Br J Haematol. 2012;157(6):732–41.CrossRefGoogle ScholarPubMed

Weissinger, EM, Metzger, J, Dobbelstein, C, Wolff, D, Schleuning, M, Kuzmina, Z, et al. Proteomic peptide profiling for preemptive diagnosis of acute graft-versus-host disease after allogeneic stem cell transplantation. Leukemia. 2014;28(4):842–52.CrossRefGoogle ScholarPubMed

Ferrara, JL, Harris, AC, Greenson, JK, Braun, TM, Holler, E, Teshima, T, et al. Regenerating islet-derived 3-alpha is a biomarker of gastrointestinal graft-versus-host disease. Blood. 2011;118(25):6702–8.CrossRefGoogle ScholarPubMed

Vander Lugt, MT, Braun, TM, Hanash, S, Ritz, J, Ho, VT, Antin, JH, et al. ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death. N Engl J Med. 2013;369(6):529–39.CrossRefGoogle ScholarPubMed